KESTRA MEDICAL TECHNOLOGIES, LTD.
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
About Kestra Medical Technologies
Surgical & Medical Instruments & Apparatus, SIC 3841
Kestra Medical Technologies, Ltd. is a medical device and digital healthcare company that develops cardiovascular monitoring and therapy technologies. Its primary offering is the Cardiac Recovery System platform, centered on the ASSURE wearable cardioverter defibrillator. The device continuously monitors cardiac rhythms and delivers defibrillation therapy upon detecting life-threatening ventricular arrhythmias. The platform also includes digital engagement applications and clinical workflow software to support care coordination and clinical insights. The company serves healthcare providers, hospitals, and patients who are at elevated risk of sudden cardiac arrest during recovery.
The company is incorporated in Bermuda and maintains its principal executive offices in Kirkland, Washington. Its commercial activities focus on the United States market. The company distributes its systems through a direct sales and customer service organization, while relying on a limited number of third-party suppliers and contract manufacturers to produce and recondition its devices and components.
Summary of the business section of Kestra Medical Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- KESTRA MEDICAL TECHNOLOGIES, LTD.
- Headquarters
- Kirkland, WA
- Address
- 3933 Lake Washington Blvd Ne, Suite 200 98033
- Phone
- (425) 279-8002
- Employees
- 443, Apr 30, 2026
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- D0
- Fiscal year ends
- April 30
- Auditor
- PricewaterhouseCoopers LLP, Irvine, California
Stock & identifiers
- Ticker
- KMTS
- Exchange
- Nasdaq
- IPO date
- Mar 6, 2025
- Shares outstanding
- 60M, Sep 11, 2026
- Public float
- $618.70M, Oct 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1877184
- CUSIP
- G52441105
- ISIN
- USG524411059
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Brian Daniel Webster | See Remarks, Director | 460,215 |
| Traci S. Umberger | See Remarks, Director | 195,825 |
| Vaseem Mahboob | Chief Financial Officer | 61,109 |
| Alfred J. Ford Jr | Chief Commercial Officer | 99,564 |
| Timothy P. Moran | Chief Business Officer | 66,345 |
| Elizabeth Kwo | Director | 14,116 |
| Jeffrey Lawrence Schwartz | Director | 25,186,574 |
| Kevin C. Reilly | Director | 12,585 |
| Mary Kay Ladone | Director | 44,724 |
| Conor Hanley | Director | 13,489 |
| Raymond W. Cohen | Director | 58,120 |
| Christopher R. Gordon | Director | 27,019,225 |
| Maxwell Bikoff | Director | – |
| Toby AuWerter | Director | – |
Employees
Headcount reported in annual reports
“As of April 30, 2026, we had over 443 full time team members, substantially all of which are located in the U.S.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 6, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 6, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |